Proving Nanotechnology Efficacy
Regulatory requirements in the pharmaceutical industry are stringent.
- Materiality
- high
Nanoform Finland Oyj
Nanoform Finland is a Finnish company specializing in nanotechnology and pharmaceutical particle engineering services. The company operates in the global pharmaceutical industry, providing expert services to enhance the bioavailability of active pharmaceutical ingredients (APIs). Nanoform's technology platform aims to address the low bioavailability of APIs, which is a significant barrier to drug approval. The company collaborates with international pharmaceutical and biotechnology companies to develop next-generation drug formulations.
173
4.32
4.21
| % | |
|---|---|
| Nanoparticle Engineering | 40% Services to enhance API bioavailability using nanotechnology. |
| Pharmaceutical Particle Technology | 30% Development of drug formulations using advanced particle technology. |
| GMP Research Services | 20% Good Manufacturing Practice compliant research services for drug development. |
| Non-GMP Research Services | 10% Research services not requiring GMP compliance for early-stage development. |
Nanoform's customers primarily include international pharmaceutical and biotechnology companies seeking to improve drug...
- Pharmaceutical Companiesprimary
Purchase nanoparticle engineering services to improve drug formulations.
- Biotechnology Firmssecondary
Use particle technology to enhance bioavailability of APIs.
- Contract Research Organizationsemerging
Require GMP and non-GMP services for clinical trials.
Nanoform is headquartered in Finland and operates globally, serving clients in the pharmaceutical and biotechnology...
- •Headquartered in Finland with global operations
- •Production and research activities based in Finland
- •Strong presence in the Nordic region
- •Collaborates with international clients in North America and Europe
Nanoform's strategic priorities include expanding its nanotechnology platform to address the low bioavailability of...
01
Expand Nanotechnology Platformmedium-term
To improve API bioavailability and increase drug approval rates.
02
Commercialize Formulationslong-term
To generate revenue from next-generation drug formulations.
03
Invest in GMP Facilitiesshort-term
To support clinical trials and ensure compliance with regulatory standards.
Nanoform faces several business and financial risks, including the challenge of proving the efficacy of its...
Growth Management
The company is in an early growth stage and may face operational challenges.
- Materiality
- medium
Technology Adoption
Pharmaceutical market's conservative nature may slow down new technology adoption.
- Materiality
- high
Currency Risks
International operations expose the company to currency fluctuations.
- Materiality
- medium
Revenue Recognition
Currency Fluctuations
Capital Expenditure
Fair Value Estimation
Orion Oyj
ORNBV.HE · Drug Manufacturers - General
Orion is a Finnish pharmaceutical company that operates globally, focusing on the development, manufacturing, and marketing of human and animal medicines, as…
Nokia Oyj
NOKIA.HE · Communication Equipment
Nokia is a Finnish multinational corporation headquartered in Helsinki, Finland.
Huhtamäki Oyj
HUH1V.HE · Packaging & Containers
Huhtamäki is a global leader in providing sustainable packaging solutions for foodservice, food, beverage, and household products.
BIOFORCE NANOSCIENCES HOLDINGS, INC.
BFNH · Laboratory Analytical Instruments
Wärtsilä Oyj Abp
WRT1V.HE · Specialty Industrial Machinery
Wärtsilä is a Finnish company specializing in innovative technologies and lifecycle solutions for the marine and energy markets.
NANOVIRICIDES, INC.
NNVC · Pharmaceutical Preparations
: 11/08/2026